U.S. FDA approves fluorescence sensing system for blood parameter monitoring
The system uses real-time optical fluorescence sensing to monitor oxygen delivery as one of 12 critical blood parameters.
Cardiovascular surgery technologies developer Terumo Cardiovascular Group (Ann Arbor, MI) has received U.S. FDA approval for its CDI Blood Parameter Monitoring System 550, which uses real-time optical fluorescence sensing to monitor oxygen delivery as one of 12 critical blood parameters. The other parameters are pH, pCO2, pO2, K+, temperature, SO2, hematocrit, hemoglobin, base excess, bicarbonate, and oxygen consumption.
Oxygen delivery (DO2) is an indicator of the amount of oxygen being delivered to a patient during cardiopulmonary bypass. Carefully monitoring DO2 has been shown to help reduce the incidence of acute kidney injury, a common complication of cardiac surgery.
Continuous in-line monitoring during cardiopulmonary bypass surgery is a critical component of perfusion safety. It quickly alerts clinicians to changes in patient status and delivers information on key parameters that helps clinicians manage perfusion cases.
The next-generation CDI System 550 offers optical fluorescence technology, a high-visibility LCD screen, advanced probe design, and IEC 60601-1 3rd Edition compliance.
For more information, please visit www.terumo-cvgroup.com.